Focal Segmental Glomerulosclerosis (FSGS) Completed Phase 2 Trials for Adalimumab (DB00051)

Also known as: Focal Glomerulosclerosis / Glomerulosclerosis, Focal / Focal Segmental Glomerulosclerosis / Glomerulosclerosis, Focal Segmental / APOL1-mediated focal segmental glomerulosclerosis / Focal & segmental glomerulosclerosis / Focal glomerular sclerosis (disorder) / Focal segmental glomerulosclerosis (disorder)

IndicationStatusPhase
DBCOND0038485 (Focal Segmental Glomerulosclerosis (FSGS))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04009668Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseBasic Science
NCT00814255Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialTreatment